Last edition
News about "central nervous system disorders"
Supernus and Indivior to Merge in All-Stock Deal to Create Diversified CNS Biopharma Leader
Supernus Pharmaceuticals and Indivior Pharmaceuticals have agreed to merge in an all-stock transaction, creating a diversified CNS-focused biopharmaceutical company with 11 marketed therapies, projected annual revenue of USD 2.2 billion and expanded capabilities in psychiatry, neurology and addiction treatment.
Central Nervous System Disorders | 04/08/2026 | By News Bureau
NMPA Clears Zhimeng Biopharma's Drug for Phase-II Epilepsy Trial
Zhimeng Biopharma’s drug for Phase II epilepsy trial will be evaluated in a randomized, double-blind, placebo-controlled multinational study to test its efficacy, safety, and tolerability as an adjunct therapy in adults with focal epilepsy.
Central Nervous System Disorders | 13/09/2025 | By Dineshwori | 271
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy